Products for Research Use Only

Tadalafil-d3

CAT: 0804-HY-90009S-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-90009S-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tadalafil-d3 is the deuterium labeled Nortadalafil. Nortadalafil is demethyl Tadalafil, which is a PDE5 inhibitor, currently marketed in pill form for treating erectile dysfunction (ED) under the name Cialis; and under the name Adcirca for the treatment of pulmonary arterial hypertension.
CAS Number
960226-55-5
Product Name Alternative
IC-351-d3
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Phosphodiesterase (PDE)
Type
Isotope-Labeled Compounds
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Cardiovascular Disease
Purity
99.40
Solubility
DMSO : 50mg/mL (ultrasonic)
Smiles
O=C1N2[C@@](C3=CC=C(OCO4)C4=C3)([H])C5=C(C[C@]2([H])C(N(C1)C([2H])([2H])[2H])=O)C6=CC=CC=C6N5
Molecular Formula
C22H16D3N3O4
Molecular Weight
392.42
Precautions
H315, H319, H335
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Beghyn, et al. PDE5 inhibitors: An original access to novel potent arylated analogues of tadalafil. Bioorganic & Medicinal Chemistry Letters (2007), 17 (3), 789-792.|[3]Daugan, et al. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogue. Journal of Medicinal Chemistry (2003), 46 (21), 4533-4542.|[4]Porst H, et al. Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily. Expert Opin Pharmacother. 2012 Jul;13 (10) :1481-94.|[5]Frey MK, Lang I. Tadalafil for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2012 Apr;13 (5) :747-55.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported